Early detection allows intervention before irreversible lung damage occurs
En el Hospital Universitario de Getafe, un equipo de neumólogos ha dado nombre a lo que antes permanecía invisible: una nueva variante genética del déficit de alfa-1 antitripsina, bautizada Pi Getafe, que deja a los pulmones y al hígado expuestos a un daño silencioso y progresivo. Durante años, pacientes con esta condición han recibido diagnósticos incompletos, atrapados en la sombra de enfermedades más conocidas. Este hallazgo, publicado en una revista científica internacional, no solo amplía el mapa genético de una enfermedad infradiagnosticada, sino que abre la puerta a intervenir antes de que el daño se vuelva irreversible.
- Pacientes con enfermedad pulmonar o hepática inexplicada llevan años sin diagnóstico mientras el daño orgánico avanza de forma silenciosa.
- La variante Pi Getafe altera el gen Serpina1, impidiendo la producción suficiente de una proteína protectora que los pulmones necesitan para defenderse del tabaco y los contaminantes ambientales.
- El equipo del Dr. Leonardo Saldaña Pérez logró distinguir esta variante como clínicamente relevante, un paso crítico en un campo donde muchas alteraciones genéticas permanecen de significado incierto.
- El descubrimiento permite ahora rastrear la enfermedad en familiares antes de que aparezcan síntomas, y diseñar estrategias terapéuticas personalizadas según el perfil genético de cada paciente.
- El Hospital de Getafe consolida su posición como referente en enfermedades respiratorias raras, señalando que el cribado genético sistemático podría revelar muchos más casos de los que la práctica clínica habitual detecta.
Los médicos del Hospital Universitario de Getafe han identificado una variante genética hasta ahora desconocida del déficit de alfa-1 antitripsina, una enfermedad que con frecuencia pasa desapercibida durante años mientras deteriora progresivamente los pulmones y el hígado. La nueva variante, denominada Pi Getafe en honor al centro donde fue descubierta, ha sido publicada en la revista Respiratory Research.
El déficit de alfa-1 antitripsina ocurre cuando el organismo no produce suficiente cantidad de una proteína que protege los pulmones frente al humo del tabaco, la contaminación y otros irritantes ambientales. Sin esa protección, los pacientes desarrollan EPOC, enfisema de inicio temprano, bronquiectasias y asma de difícil control, además de daño hepático, sin que muchos lleguen a relacionar estas afecciones con una causa genética común.
El trabajo, liderado por el Dr. Leonardo Saldaña Pérez, jefe de la unidad especializada en EPOC del hospital, se centra en una nueva alteración del gen Serpina1. Identificar esta variante como clínicamente relevante es un avance significativo, ya que en genética no toda variación detectada tiene consecuencias claras para la salud.
Las implicaciones prácticas son considerables: la detección precoz permite intervenir antes de que el daño pulmonar sea irreversible, aconsejar a los pacientes que eviten el tabaco y las exposiciones tóxicas laborales, y ofrecer cribado genético a sus familiares. Para quienes llevan años con una enfermedad respiratoria sin explicación, este hallazgo puede suponer por fin un diagnóstico y un camino hacia un tratamiento adaptado a su perfil genético específico.
El caso de Pi Getafe ilustra también un problema más amplio: las enfermedades genéticas raras suelen confundirse con patologías comunes. Un enfisema precoz se atribuye al tabaquismo; una hepatopatía progresiva se investiga como hepatitis. Sin pruebas genéticas, la causa real permanece oculta. La investigación de Getafe sugiere que un cribado más sistemático en pacientes con enfermedades respiratorias atípicas o inexplicadas podría sacar a la luz muchos más casos de los que hoy se diagnostican.
Doctors at Getafe University Hospital in Madrid have identified a previously unknown genetic variant of alpha-1 antitrypsin deficiency, a condition so often missed that patients can spend years suffering progressive lung and liver damage without understanding why. The discovery, named Pi Getafe after the hospital where it was found, represents a significant step forward in understanding a disease that remains dramatically underdiagnosed across the medical system.
Alpha-1 antitrypsin deficiency occurs when the body fails to produce adequate amounts of a protective protein that shields the lungs from damage caused by tobacco smoke, air pollution, and other environmental irritants. Without sufficient protection, patients develop serious respiratory conditions including chronic obstructive pulmonary disease, early-onset emphysema, bronchiectasis, and difficult-to-control asthma. The disease also damages the liver, creating a dual threat to organs that many patients never connect to a single underlying genetic cause.
The research team, led by Dr. Leonardo Saldaña Pérez, a pulmonologist and head of the hospital's specialized COPD clinic, published their findings in the journal Respiratory Research. The work centers on a new variant of the Serpina1 gene, the genetic instruction set responsible for producing alpha-1 antitrypsin. By identifying this variant, the researchers have expanded the medical understanding of which genetic alterations actually matter clinically—a crucial distinction in a field where genetic testing can sometimes reveal variations of unclear significance.
The practical implications are substantial. Early detection of this newly identified variant allows physicians to intervene before irreversible lung damage occurs. Patients can be counseled to avoid smoking and occupational exposures to toxic substances. Family members can be screened through genetic testing programs to identify others who carry the variant before symptoms appear. For patients whose respiratory disease has remained unexplained despite standard diagnostic workup, this discovery offers a potential explanation and a path toward targeted treatment.
Saldaña emphasized that the finding opens doors to developing new therapeutic approaches tailored to the specific genetic profile of individual patients. Rather than applying a one-size-fits-all treatment strategy, clinicians can now consider the particular genetic variant a patient carries when designing their care plan. This represents a shift toward precision medicine in respiratory disease—treating not just the symptoms but the underlying genetic mechanism driving them.
The identification of Pi Getafe also highlights a broader challenge in medicine: rare genetic diseases often go unrecognized because they present with common symptoms. A patient with early emphysema might be assumed to be a heavy smoker. Someone with progressive liver disease might be investigated for hepatitis or alcohol use. Without genetic testing, the true cause remains hidden, and the opportunity for early intervention passes. Getafe Hospital's work suggests that systematic genetic screening of patients with unexplained or atypical respiratory disease could identify many more cases of alpha-1 antitrypsin deficiency than current practice detects.
The hospital has positioned itself as a center of excellence in diagnosing rare respiratory diseases, and this discovery reinforces that reputation. The research team's ability to identify a novel genetic variant and publish it in a peer-reviewed international journal demonstrates the caliber of work being conducted there. For patients with alpha-1 antitrypsin deficiency—whether they carry the newly identified Pi Getafe variant or other known forms—the discovery signals that medical science is paying closer attention to their condition and developing better tools to catch it early.
Notable Quotes
This discovery allows identification of patients who were unaware they had the disease and opens new avenues for investigating possible therapeutic strategies— Dr. Leonardo Saldaña Pérez, pulmonologist at Getafe University Hospital
The Hearth Conversation Another angle on the story
Why does a disease this serious remain so underdiagnosed? It seems like something doctors would catch routinely.
Because it mimics other conditions. A patient with emphysema looks like a smoker. Someone with liver disease looks like they have hepatitis. Without genetic testing, you never know to look for the underlying defect. Most hospitals don't screen for it unless they have a specific reason to suspect it.
And this new variant—Pi Getafe—how does it change what doctors can actually do?
It gives them a name for something they couldn't identify before. Once you know what you're looking for genetically, you can test for it. You can tell a patient: this is why your lungs are failing, and here's what we need to do to slow it down.
Can you reverse the damage that's already happened?
No. That's the tragedy of underdiagnosis. By the time someone finds out they have it, there's often significant scarring. But you can prevent further damage. You can tell them to quit smoking, avoid toxic exposures, and you can screen their family members before they develop symptoms.
So early detection is really the only weapon here.
It's the main one. That's why this discovery matters so much. Every patient they identify early is someone who might avoid years of progressive disease.
What happens to the patients who already have the disease but don't know it yet?
They keep getting sicker. They see different doctors, get different diagnoses, try different treatments that don't address the root cause. Some eventually figure it out. Many don't.